Lecanemab (brand name Leqembi) is the only FDA-approved drug of its class for Alzheimer's patients, showing moderate delays in disease progression but with significant side effects.
Patients must meet strict criteria to receive lecanemab, including diagnosis of mild cognitive impairment, presence of amyloid plaques, and exclusion of other brain diseases.
[
add
]
[
|
|
...
]